Prothena reports Q3 net income of $109.2M vs loss; revenue $139.2M on partner payments

PROTHENA CORP PUBLIC LTD CO

2021-Q3 EPS reported $2.12 revenue$199,405,000

Q3 net income $109.2M ($2.13 diluted EPS) vs net loss $30.6M a year ago; 9-month net income $100.2M.
Revenue $139.2M, driven by $78.5M BMS option for PRX005 US license and $60.7M IP sale to Novo Nordisk.
Cash, equivalents and restricted cash $601.5M at Sept 30, 2021; no debt.
Updated FY2021 guidance: year-end cash ~$575M, net cash from ops/investing $85-95M, net income $50-60M.
Appointed Tran Nguyen as CFO and Chief Strategy Officer; Brandon Smith as COO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.